vs
Paylocity Holding Corp（PCTY）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Paylocity Holding Corp的季度营收约是Ultragenyx Pharmaceutical Inc.的1.9倍（$387.0M vs $207.3M），Paylocity Holding Corp净利率更高（13.0% vs -62.0%，领先75.0%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 11.3%），Paylocity Holding Corp自由现金流更多（$113.6M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 2.7%）
Paylocity Holding Corp是美国领先的云端人力资源管理服务商，核心产品覆盖薪资核算、支出管理及人力资本管理（HCM）类SaaS软件，可帮助不同规模的企业客户优化人力与财务相关运营流程，有效提升管理效率、降低运营成本。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
PCTY vs RARE — 直观对比
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $387.0M | $207.3M |
| 净利润 | $50.2M | $-128.6M |
| 毛利率 | 72.9% | — |
| 营业利润率 | 18.2% | -54.7% |
| 净利率 | 13.0% | -62.0% |
| 营收同比 | 11.3% | 25.9% |
| 净利润同比 | 34.0% | 3.5% |
| 每股收益（稀释后） | $0.92 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $387.0M | $207.3M | ||
| Q3 25 | $378.9M | $159.9M | ||
| Q2 25 | $369.9M | $166.5M | ||
| Q1 25 | $421.1M | $139.3M | ||
| Q4 24 | $347.7M | $164.6M | ||
| Q3 24 | $333.1M | $139.5M | ||
| Q2 24 | $324.7M | $147.0M | ||
| Q1 24 | $366.8M | $108.8M |
| Q4 25 | $50.2M | $-128.6M | ||
| Q3 25 | $48.0M | $-180.4M | ||
| Q2 25 | $48.6M | $-115.0M | ||
| Q1 25 | $91.5M | $-151.1M | ||
| Q4 24 | $37.5M | $-133.2M | ||
| Q3 24 | $49.6M | $-133.5M | ||
| Q2 24 | $48.8M | $-131.6M | ||
| Q1 24 | $85.3M | $-170.7M |
| Q4 25 | 72.9% | — | ||
| Q3 25 | 73.9% | — | ||
| Q2 25 | 73.5% | — | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 72.6% | — | ||
| Q3 24 | 74.4% | — | ||
| Q2 24 | 74.0% | — | ||
| Q1 24 | 77.8% | — |
| Q4 25 | 18.2% | -54.7% | ||
| Q3 25 | 19.6% | -106.9% | ||
| Q2 25 | 17.9% | -64.8% | ||
| Q1 25 | 30.2% | -102.6% | ||
| Q4 24 | 13.4% | -74.3% | ||
| Q3 24 | 19.3% | -94.6% | ||
| Q2 24 | 19.4% | -79.1% | ||
| Q1 24 | 29.0% | -151.9% |
| Q4 25 | 13.0% | -62.0% | ||
| Q3 25 | 12.7% | -112.8% | ||
| Q2 25 | 13.1% | -69.0% | ||
| Q1 25 | 21.7% | -108.5% | ||
| Q4 24 | 10.8% | -80.9% | ||
| Q3 24 | 14.9% | -95.7% | ||
| Q2 24 | 15.0% | -89.5% | ||
| Q1 24 | 23.3% | -156.8% |
| Q4 25 | $0.92 | $-1.28 | ||
| Q3 25 | $0.86 | $-1.81 | ||
| Q2 25 | $0.87 | $-1.17 | ||
| Q1 25 | $1.61 | $-1.57 | ||
| Q4 24 | $0.66 | $-1.34 | ||
| Q3 24 | $0.88 | $-1.40 | ||
| Q2 24 | $0.85 | $-1.52 | ||
| Q1 24 | $1.50 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $162.5M | $421.0M |
| 总债务越低越好 | $81.3M | — |
| 股东权益账面价值 | $1.1B | $-80.0M |
| 总资产 | $7.0B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
| Q4 25 | $162.5M | $421.0M | ||
| Q3 25 | $165.2M | $202.5M | ||
| Q2 25 | $398.1M | $176.3M | ||
| Q1 25 | $477.8M | $127.1M | ||
| Q4 24 | $482.4M | $174.0M | ||
| Q3 24 | $778.5M | $150.6M | ||
| Q2 24 | $401.8M | $480.7M | ||
| Q1 24 | $492.7M | $112.3M |
| Q4 25 | $81.3M | — | ||
| Q3 25 | $81.3M | — | ||
| Q2 25 | $162.5M | — | ||
| Q1 25 | $243.8M | — | ||
| Q4 24 | $325.0M | — | ||
| Q3 24 | $325.0M | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.1B | $-80.0M | ||
| Q3 25 | $1.1B | $9.2M | ||
| Q2 25 | $1.2B | $151.3M | ||
| Q1 25 | $1.2B | $144.2M | ||
| Q4 24 | $1.2B | $255.0M | ||
| Q3 24 | $1.1B | $346.8M | ||
| Q2 24 | $1.0B | $432.4M | ||
| Q1 24 | $1.1B | $140.3M |
| Q4 25 | $7.0B | $1.5B | ||
| Q3 25 | $4.2B | $1.2B | ||
| Q2 25 | $4.4B | $1.3B | ||
| Q1 25 | $5.2B | $1.3B | ||
| Q4 24 | $5.3B | $1.5B | ||
| Q3 24 | $4.0B | $1.5B | ||
| Q2 24 | $4.2B | $1.6B | ||
| Q1 24 | $5.0B | $1.3B |
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.07× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.20× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 0.29× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $117.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $113.6M | $-100.8M |
| 自由现金流率自由现金流/营收 | 29.4% | -48.6% |
| 资本支出强度资本支出/营收 | 0.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.33× | — |
| 过去12个月自由现金流最近4个季度 | $461.1M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $117.0M | $-99.8M | ||
| Q3 25 | $86.5M | $-91.4M | ||
| Q2 25 | $86.6M | $-108.3M | ||
| Q1 25 | $186.0M | $-166.5M | ||
| Q4 24 | $54.2M | $-79.3M | ||
| Q3 24 | $91.5M | $-67.0M | ||
| Q2 24 | $79.9M | $-77.0M | ||
| Q1 24 | $167.5M | $-190.7M |
| Q4 25 | $113.6M | $-100.8M | ||
| Q3 25 | $82.7M | $-92.7M | ||
| Q2 25 | $81.1M | $-110.7M | ||
| Q1 25 | $183.7M | $-167.8M | ||
| Q4 24 | $51.2M | $-79.5M | ||
| Q3 24 | $89.1M | $-68.6M | ||
| Q2 24 | $73.6M | $-79.0M | ||
| Q1 24 | $162.0M | $-193.9M |
| Q4 25 | 29.4% | -48.6% | ||
| Q3 25 | 21.8% | -58.0% | ||
| Q2 25 | 21.9% | -66.5% | ||
| Q1 25 | 43.6% | -120.5% | ||
| Q4 24 | 14.7% | -48.3% | ||
| Q3 24 | 26.8% | -49.2% | ||
| Q2 24 | 22.7% | -53.7% | ||
| Q1 24 | 44.2% | -178.2% |
| Q4 25 | 0.9% | 0.5% | ||
| Q3 25 | 1.0% | 0.8% | ||
| Q2 25 | 1.5% | 1.5% | ||
| Q1 25 | 0.5% | 1.0% | ||
| Q4 24 | 0.9% | 0.1% | ||
| Q3 24 | 0.7% | 1.2% | ||
| Q2 24 | 1.9% | 1.4% | ||
| Q1 24 | 1.5% | 3.0% |
| Q4 25 | 2.33× | — | ||
| Q3 25 | 1.80× | — | ||
| Q2 25 | 1.78× | — | ||
| Q1 25 | 2.03× | — | ||
| Q4 24 | 1.45× | — | ||
| Q3 24 | 1.84× | — | ||
| Q2 24 | 1.64× | — | ||
| Q1 24 | 1.96× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCTY
| Recurring Fees | $370.1M | 96% |
| Implementation Services And Other | $16.9M | 4% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
